Phaseline

Companies › Pharmazz

Pharmazz: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 2 Phase 4, 2 Phase 2, 1 Phase 3; Other, Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Centhaquine (LYFAQUIN™)
α2B-adrenergic receptor agonist (venous) and α2A-adrenergic receptor agonist (arterial); e
ADRA2B, ADRA2APhase 4Hypovolemic ShockNov 2026
Sovateltide
ETB receptor agonist
EDNRBPhase 4Acute Cerebral Ischemia; Acute Ischemic Stroke; Hypoxic-Ischemic EncephalopathyNov 2026
PMZ-1620
Endothelin-B receptor agonist
EDNRBPhase 2Acute Spinal Cord Injury–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04054414PMZ-1620Phase 2Acute Spinal Cord InjuryNeurologyJun 2026
NCT05956418Centhaquine (LYFAQUIN™)Phase 4Hypovolemic ShockOtherNov 2026
NCT05514340SovateltidePhase 2Hypoxic-Ischemic EncephalopathyOtherNov 2026
NCT05955326SovateltidePhase 4Acute Cerebral IschemiaNeurologyDec 2026
NCT05691244SovateltidePhase 3Acute Ischemic StrokeNeurologySep 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

EDNRB (2) ADRA2B (1) ADRA2A (1)

Companies with the same targets

Guangzhou Novaken Pharm BioXcel Therapeutics Teikoku Pharma USA Tarian Pharma Alcon Research Acer Therapeutics Noorik Biopharmaceuticals Johnson & Johnson (Janssen) Santen SAS ARS Pharmaceuticals

Companies built like this

Chongqing Claruvis Pharmaceutical Harmony Biosciences Management argenx Epygenix Incepta Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.